Organisation paid for research Program year 2025 Source: CMS Open Payments

BioKinetic Clinical Applications LLC

Neither a doctor nor a teaching hospital

Research payments

$2,406,663

97 payments

Through program year 2025, BioKinetic Clinical Applications LLC is reported as receiving $2,406,663 in research payments, across 97 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $169,398 19
2024 Research $454,874 36
2023 Research $773,942 33
2022 Research $761,505 3
2020 Research $54,927 1
2019 Research $192,017 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $1,420,338 90 payments
  2. Biogen, Inc. $739,381 1 payment
  3. DPT Laboratories, Ltd. $240,423 3 payments
  4. Sanofi Pasteur Inc. $6,521 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers $739,381 1 payment
  2. A Phase 23 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Vaccine Candidates for Sarscov2 New Variants in Healthy Individuals $397,920 25 payments
  3. A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $323,404 10 payments
  4. A Phase 3 Master Protocol to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults at High Risk of Severe RSV Disease $258,419 14 payments
  5. Bdrf-18054 $240,423 3 payments
  6. A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Covid19 Vaccine and A Recombinant Influenza Vaccine Administered As A Single Injection in Healthy Adults 50 Years of Age Or Older $114,701 7 payments
  7. A Phase 3 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Variantadapted Vaccine Candidates Against Sarscov2 in Participants 12 Through 64 Years of Age Considered at Higher Risk of Severe Covid19 and Participants 65 Years of Age $106,673 5 payments
  8. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $104,723 15 payments
  9. A Phase 12 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $85,283 11 payments
  10. A Phase 1 Randomized Doubleblind Sponsoropen Study to Describe the Safety and Tolerability of A Multivalent Pneumococcal Conjugate Vaccine in Adults $11,879 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Other $240,423 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record